AirMid Critical Care Products, Inc.

Medical breakthrough to replace 60 year-old n...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9




 

AirMid’s VCMV device will be the first manual ventilator able to deliver guideline-compliant breath sizes
Because breath size can be “dialed in” to match the guideline-prescribed amount tailored to each individual patient, this means AirMid’s VCMV device provides an opportunity to advance a standard that has waited over sixty years without improvement 

Upon FDA clearance, AirMid’s technology will singularly enable hospitals to comply with existing safety guidelines to protect patients from lung injury, and in so doing help decrease complications by 61.8%, patient deaths by 42%, and contribute to as much as $12.4 billion in cost savings per year in the U.S. alone 

To understand how AirMid will achieve this, an introduction to the attributes of Acute Lung Injury (ALI) and existing clinical evidence providing these figures are needed.



Every year approximately 5% of newborns worldwide (about 7 million) require positive pressure ventilation (PPV) to help them start breathing on their own

This is most often provided by a 1950s-era manual ventilator (or “self-inflating bag”)

Research shows medical caregivers of all skill levels – even doctors – inadvertely over-inflate in 73.8% of cases, putting newborns at risk of Acute Lung Injury

Based on CDC data, the #1 cause of death of patients aged 0-15 is trauma, with traumatic brain injury being the primary risk of death in children 0-4 years of age

The treatment for severe traumatic brain injury is medically-induced coma, meaning artificial ventilation is required (and almost always instituted with a non-compliant manual ventilator)

During treatment of brain injury, lung injury is a high-risk complication

According to two recent landmark studies, patients undergoing general anesthesia for surgery or being treated in ERs are at risk of – and actually develop – ALI

In all clinical settings, artificial ventilation is almost always initiated with non-compliant manual ventilators

Currently, there are only two options to provide artificial ventilation, each representing a compromise between advantages and disadvantages


AirMid’s Volume-Controlled Manual Ventilator (VCMV) incorporates a simple volume-control mechanism in place of the uncontrollable bag on existing products (leaving everything else the same)

This retains convenience factors and familiarity of current devices, while adding ability to protect patients from torn lungs by enabling ventilation within lung-protective guidelines

As a result, AirMid’s VCMV utilizes a proprietary mechanism to combine the best attributes of both current modalities to effectively advance manual ventilation to a new standard

MAXIMIZED DISRUPTION

AirMid anticipates no future role for non-compliant 1950s-era manual ventilators once the guideline-compliant AirMid VCMV emerges on the market, providing a safer clinical alternative

Current manual ventilators are all non-compliant with existing American Heart Association (AHA) guidelines (the AHA is the leading U.S. authority regarding resuscitation practices and standards).  These single-use/disposible products range in pricing from $10 per unit to over $70 per unit for “premium” versions that offer no advantage in operation or patient safety. 

This, in itself, offers a remarkable opportunity which is further enhanced by the fact that the downstream costs associated with lung injuries exceed $20 billion annually in the U.S.




Recent studies have shown that if ventilation is delivered within lung-protective guidelines, meaning over-inflation is prevented and the lungs are not exposed to tearing injuries, then complications and mortality decrease markedly


Michael will lead the enterprise given his deep technical and clinical knowledge of the trauma, critical care and resuscitation space and surrounding science

Michael began working as an ambulance EMT in Vermont at the age of 16

He invented his first patented medical device at age 19 while undergoing a two-year military training program to become a cardiopulmonary technician for the US Air Force; he individually invented the VCMV

He has since developed substantial startup business administration knowledge and experience that, combined with other experienced team members, provides stable leadership for the enterprise

As Managing Director, Peter will assist Michael in administering the enterprise but will also lead investor relations and AirMid’s business development and strategy functions

Peter is an experienced entrepreneur and AirMid investor, having a diverse background including experience in various executive management positions with Fortune 500 companies and small cap private enterprises

A key focus area for Peter – and particular area of success – is developing robust business development, scaling and monetization plans that optimize and leverage disruptive intellectual property portfolios

In her primary operational role, Kristy will program manage all VCMV development programs and implement AirMid’s ISO 13485-compliant Quality Management System (essential for international market clearances)

She has over 25 years of top-level experience in the medical device industry spanning concept-to-launch-to-post-market quality surveillance of medical devices ranging from simple static tools through complex electronic implantable devices

Kristy gained her experience working in leadership roles at companies including Kimberly Clark, Medtronic Cardiovascular and Edwards Lifesciences

Paul will lead our ISO-certified product development vendors during VCMV final engineering in order to guide the product to an ideal embodiment of practical function, usability, and form

He will also assist the CEO in business management and product strategy activities given his GM/startup experience

Paul’s postgraduate education includes aptitudes in biomedical engineering, industrial design, and product development – he brings 30 years of experience merging these three fields in medical device design and development

Dr Peck will serve as Chief Medical Officer (CMO) guiding AirMid’s team in its interface with clinical stakeholders

Dr Peck is currently an anesthesiologist in the Johns Hopkins Health Network, advises multiple medical startups, and has also served as Assistant Professor of Neuroanesthesia at George Washington University

Dr Sackier will work with Dr Peck in his CMO role and with the CEO and investment community to guide fundraising and investor relations given his extensive track record with early stage companies (primarily in CMO positions of his own)

An internationally-renowned inventor of patented medical technologies himself, Dr Sackier brings extensive experience gained over more than 30 years in the healthcare industry

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.